Intelligence · Patents
Patents expiring in 2043
Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.
- Patents
- 1,718
Quick answer
1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11572575
Compositions for transfecting resistant cell types
granted -
US 11571466
Compositions and methods for treating Gaucher disease
granted -
US 11572377
Nucleotide analogs
granted -
US 11571389
Delivery devices and methods for making the same
granted -
US 11571445
Genetically engineered hematopoietic stem cells and uses thereof
granted -
US 11572591
Methods and assays for subtyping Staphylococcus aureus clonal complex 8 strains
granted -
US 11571636
Methods for quantitating individual antibodies from a mixture
granted -
US 11571484
Compositions that target tumor-associated macrophages and methods of use therefor
granted -
US 11571440
Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
granted -
US 11571412
Thromboxane receptor antagonists in AERD/asthma
granted -
US 11571428
Pharmaceutical compositions comprising meloxicam
granted -
US 11572334
Methods for making and using endoxifen
granted -
US 11571538
Gas delivery devices
granted -
EP 4125971
BAKTERIENSTÄMME, ZUSAMMENSETZUNGEN DAVON UND VERWENDUNG DAVON IN EINEM VERFAHREN ZUR BEHANDLUNG VON VITAMIN-D-MANGEL UND DAMIT ASSOZIIERTEN ERKRANKUNGEN
granted -
US 2023040008
ANTI-HER2 POLYPEPTIDES DERIVATIVES AS NEW DIAGNOSTIC MOLECULAR PROBES
granted -
US 11576356
Genetically modified non-human animals and methods of use thereof
granted -
US 11576863
Formulation of an antibody and use thereof
granted -
US 11576907
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 11576983
Treatments for retinal disease
granted -
US 11578371
Biomarkers for predicting tumor response to and toxicity of immunotherapy
granted -
US 11578135
Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof
granted -
US 11578313
CRISPR-Cas effector polypeptides and methods of use thereof
granted -
US 11578309
Universal donor cells
granted -
US 11578078
Heterocyclic RIP1 inhibitory compounds
granted -
US 11578127
Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof
granted -
US 11576984
Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
granted -
US 11578315
Truncated guinea pig L-asparaginase variants and methods of use
granted -
US 11576924
Compounds for the prevention and treatment of diseases and the use thereof
granted -
US 11578066
Fluoroalkyl-oxadiazoles and uses thereof
granted -
US 11576948
Long-acting VEGF inhibitors for intraocular neovascularization
granted -
US 11579150
Methods for characterizing disulfide bonds
granted -
US 11578338
Hemipteran active insecticidal protein
granted -
US 11576871
Formulations of cysteamine and cystamine
granted -
US 11576883
L-DOPA microbiome therapy
granted -
US 11576982
Nipah virus envelope pseudotyped lentiviruses and methods of their use
granted -
US 11576580
Apparatus, systems and methods for intraoperative imaging
granted -
US 11576744
Thermosensitive bio-adhesive hydrogel for removal of ureteral and renal stones
granted -
US 11576951
Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
granted -
US 11578081
Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof
granted -
US 11578126
Chimeric antigen receptor (CAR) comprising a CD19-binding domain
granted -
US 11578103
Nucleic acids encoding Zika virus-like particles and their use in Zika virus vaccines and diagnostic assays
granted -
US 11576971
Method of filling a container with no headspace
granted -
US 11576889
Methods of identifying and treating patients with HIF-2 inhibitor resistance
granted -
US 11578062
Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
granted -
US 11576922
CD73 inhibitors
granted -
US 11583542
Compositions of bile acids and phenylbutyrate compounds
granted -
US 11584780
Adeno-associated virus capsid proteins
granted -
US 11584933
RNA interference in ocular indications
granted
Frequently asked questions
How many pharma patents expire in 2043?
1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.